Please login to the form below

Not currently logged in
Email:
Password:

Basilea appoints commercial head

David Veitch spent 15 years at BMS

Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.

Veitch will lead the company's commercial operations, including sales, marketing and pricing.

He joins from Savient Pharmacueticals where he served as president of the company's' European operations. It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.

Veitch's most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.

Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.

19th August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics